Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor to Present at Upcoming Investor Conferences
MONROVIA, Calif. , Sept. 20, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will
View HTML
Toggle Summary Xencor Reports Second Quarter 2017 Financial Results
-- Management to Host Conference Call Today at 4:30 p.m. ET --
View HTML
Toggle Summary Xencor to Present at Upcoming Investor Conferences
MONROVIA, Calif. , Aug. 2, 2017 /PRNewswire/ -- Xencor , Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will
View HTML
Toggle Summary Xencor to Host Second Quarter 2017 Financial Results Webcast and Conference Call on August 7, 2017
MONROVIA, Calif. , July 31, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release second quarter
View HTML
Toggle Summary Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017
- 14 of 15 patients (93%) achieved a response to therapy, 12 of them within 2 weeks of first dose -- 6 patients attained disease remission (an IgG4-RD Responder Index of 0) -- Every other week intravenous administration of XmAb5871 in patients with active IgG4-RD has been well tolerated -
View HTML
Toggle Summary Xencor Appoints Raphael Clynes, M.D., Ph.D., as Vice President of Translational Biology
MONROVIA, Calif. , June 8, 2017 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Raphael Clynes
View HTML
Toggle Summary Xencor to Present at Jefferies 2017 Global Healthcare Conference
MONROVIA, Calif. , May 30, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that Bassil Dahiyat, Ph.D.,
View HTML
Toggle Summary Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
MONROVIA, Calif. , May 11, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced today that XmAb®5871 has been granted
View HTML
Toggle Summary Xencor Reports First Quarter 2017 Financial Results
-- Phase 1 Data from Subcutaneous Administration Trial of XmAb®5871 Support Biweekly Dosing ---- Management to Host Conference Call Today at 4:30 p.m. ET --
View HTML
Toggle Summary Xencor to Host First Quarter 2017 Financial Results Webcast and Conference Call on May 9, 2017
MONROVIA, Calif. , May 2, 2017 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced that it will release first quarter 2017
View HTML
Xencor © Copyright 2018